KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

There are many mechanisms at work here, but the blood sugar increase is probably secondary to the weight gain, rather than ...

But here’s a little insider info: Ozempic’s just the show name. The real star? Semaglutide, the active ingredient doing all ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

The intricate landscape of medical research continues to unveil groundbreaking approaches to managing chronic joint health ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

A total of nearly 137 million adults, representing more than half of all U.S. adults, are eligible for semaglutide therapy. This ...

A retrospective cohort study using data from patients in 21 countries showed use of semaglutide use was not linked to an ...

Semaglutide, the active ingredient in Ozempic, has shown promising results in weight loss and blood sugar management. But did ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...